← All Sponsors
SPONSOR

XIANG YANQUN

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: Nasopharyngeal Carcinoma
NCT06383780 Phase 3
Recruiting

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Nasopharyngeal Carcinoma
China View Trial →